mezlocillin
Trade name: mezlin
Approved
Sep 21, 1981
Bayer developed MEZLOCILLIN (previously known as BAYPEN); it is a semisynthetic ampicillin-derived penicillin. Mezlocillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The bactericidal activity of mezlocillin results from the inhibition of cell wall synthesis and is mediated through mezlocillin binding to penicillin binding proteins (PBPs). Mezlocillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases and cephalosporinases and extended spectrum beta-lactamases. Mezlocillin was poorly absorbed orally and was given either intramuscularly or intravenously. This drug was discontinued in the U.S. — NCATS
Clinical trial activity
2 trials · 4 clinical orgs · 1 marketing orgs
Earliest trial started Aug 1, 2013 (NCT01931150)
Timeline
Indications
Approved for
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Approval history
- approvedSep 21, 1981
Chemistry & pharmacology
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O- Mol. weight
- 539.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1731 ↗
- WikipediaMezlocillin ↗
- NCATSOH2O403D1G ↗
- ChEMBLCHEMBL1697708 ↗
Also known as
- (2s,5r,6r)-3,3-dimethyl-6-{[(2r)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- (2s,5r,6r)-3,3-dimethyl-6-{[(2r)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- 6beta-{(2r)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid
- 6beta-{(2r)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid
- baypen
- baypen
- mezlin
- mezlin
- mezlin
- mezlocilina
- mezlocilina
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocillin
- mezlocilline
- mezlocilline
- mezlocillin sodium
- mezlocillin sodium
- mezlocillin sodium
- mezlocillin sodium monohydrate
- mezlocillin sodium monohydrate
- mezlocillin sodium monohydrate
- mezlocillin sodium monohydrate
- mezlocillinum
- mezlocillinum
- multocillin
- multocillin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02099240 | Early Phase 1 (Phase 1) | Apr 1, 2014 | James Graham Brown Cancer Center, University of Louisville |
| NCT01931150 | Phase 3 | Aug 1, 2013 | Bristol-Myers Squibb, Cornell University |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2013 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| James Graham Brown Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Louisville | Academic/Hospital | 1 | 1 | 1 | 2014 |